[Market Focus] Lunit Drops on Concerns Over Widening Losses

As of exactly 2:00 p.m. on November 13, 2025, shares of the AI bio company Lunit were trading at 39,425 won on the KOSDAQ market, down 16.65% from the previous day's closing price. This appears to be due to concerns that the timeline for turning a profit will be delayed as the company's losses have continued to grow year after year.

Lunit generates revenue through its flagship AI cancer diagnosis platform "Lunit Insight," its AI cancer treatment biomarker platform "Lunit Scope," and its wholly owned subsidiary "Volpara."

According to the consolidated financial statements, Lunit's revenue (operating income) was 25.1 billion won in 2023, 54.2 billion won in 2024, and 56.7 billion won as of the end of the third quarter this year. However, operating losses also increased, reaching 42.2 billion won in 2023 and 67.9 billion won in 2024. By the end of the third quarter this year, the operating loss stood at 63.5 billion won, with annual losses expected to approach 80 billion won.

Previously, when Lunit went public in 2022, the company set a goal of turning a profit by 2024. However, it has since pushed back this target twice, first to 2025 and then to 2027. The company has recently implemented self-rescue measures, including a restructuring that reduced its total workforce by about 15%.

This content was produced with the assistance of AI translation services.